Young Woo Do

Dr. Young Woo Do


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EGEun-Young Gong
Eun-Young Gong
HLHye Won Lee
Hye Won Lee
HOHyunseung Oh
Hyunseung Oh
JLJae-Ho Lee
Jae-Ho Lee
SBSang Jun Byun
Sang Jun Byun
YDYoung Woo Do
Young Woo Do
Radiotherapy is the central component in non-small cell lung cancer (NSCLC) treatment. Nonetheless, its therapeutic effectiveness is frequently compromised by adaptive engagement of prosurvival signaling pathways that foster radioresistance. STAT3 functions as the central signaling node that orchestrates cellular survival responses following radiation exposure. This study investigated whether nitroxoline, a clinically approved antimicrobial agent with STAT3-inhibitory activity, enhances radiosensitivity of NSCLC cells and how these effects are mechanistically regulated. We examined the combined effects of nitroxoline and radiation on cell viability and associated signaling pathways in NSCLC cells. Nitroxoline significantly enhanced radiation-induced cytotoxicity and suppressed clonogenic survival compared with radiation alone. Irradiation increased STAT3, AKT, and mTOR phosphorylation, whereas nitroxoline effectively suppressed the basal and radiation-induced activation of these pathways. The combination treatment markedly augmented radiation-induced apoptosis, as demonstrated by increased p53 expression and enhanced PARP and caspase-3 cleavage. Additionally, nitroxoline amplified radiation-induced DNA damage signaling, resulting in pronounced γ-H2AX and DNA-PKcs accumulation. Nitroxoline enhanced NSCLC cell radiosensitivity by suppressing STAT3–AKT–mTOR survival signaling, promoting apoptosis, and amplifying radiation-induced DNA damage, indicating the potential of repurposing nitroxoline as a radiosensitizer to improve radiotherapy outcomes in patients with NSCLC.

22 September 2026 in Genes
Verified
Journal Article
Open access
PDF file
SSSEONGWON SHIN
SEONGWON SHIN
CJChi Young Jung
Chi Young Jung
MHMi Jeong Hong
Mi Jeong Hong
JLJang Hyuck Lee
Jang Hyuck Lee
WLWon Kee Lee
Won Kee Lee
JCJin Eun Choi
Jin Eun Choi
Background/Objectives: Genetic variation in components of the ubiquitin–proteasome system may contribute to cancer progression and clinical outcomes. This study investigated whether potentially functional variants in E3 ubiquitin ligase-related genes are associated with survival outcomes after surgical resection of non-small cell lung cancer (NSCLC). Methods: The study included 744 Korean patients with stage I–IIIA NSCLC, divided into discovery and validation cohorts. Fifty-one potentially functional single-nucleotide polymorphisms in E3 ubiquitin ligase-related genes were evaluated for associations with overall survival (OS) and disease-free survival (DFS). Results: Among the polymorphisms examined, BTRC rs10883617 T>C was significantly associated with DFS in the validation cohort, whereas the association with OS showed a concordant trend but did not reach statistical significance. In the combined cohort, carriers of at least one C allele had significantly better OS (HR = 0.55, 95% CI = 0.34–0.90, p = 0.02) and DFS (HR = 0.64, 95% CI = 0.46–0.89, p = 0.01) than patients with the TT genotype. The C allele demonstrated significantly lower promoter activity than the T allele in A549 and H1299 lung cancer cell lines (both p < 0.01). BTRC mRNA expression was significantly higher in tumor tissues than in paired non-neoplastic tissues (p < 0.001), but did not differ by genotype. Conclusions: Collectively, BTRC rs10883617 T>C was associated with favorable survival outcomes and allele-specific promoter activity in surgically resected NSCLC. However, its effect on endogenous BTRC expression remains unconfirmed in this patient population. Independent external validation and further mechanistic studies are warranted.